BMO starts coverage on Integra with $19 target
BMO Capital analyst Vik Chopra has initiated coverage on Integra Lifesciences (NASDAQ: IART) with a Market Perform rating and a price target of $19, establishing a new valuation benchmark for the medical technology company.

*this image is generated using AI for illustrative purposes only.
BMO Capital analyst Vik Chopra has initiated coverage on Integra Lifesciences (NASDAQ: IART) with a Market Perform rating and a price target of $19. This new assessment provides a fresh valuation perspective on the medical technology company's stock performance.
Rating and Target Details
The brokerage firm's decision to assign a Market Perform rating suggests a balanced view of the stock's potential relative to the broader market. The price target of $19 establishes a specific valuation benchmark for investors monitoring the company.
| Metric | Value |
|---|---|
| Rating | Market Perform |
| Price Target | $19 |
| Exchange | NASDAQ |
| Ticker Symbol | IART |
What specific catalysts could drive Integra Lifesciences' stock above the $19 price target?
How might upcoming clinical trial results influence future analyst ratings for IART?
What are the potential risks that could lead to a downgrade from the current Market Perform rating?


























